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Abstract: A growing understanding of the biology of renal cell carcinoma (RCC) has led to the 
development and US Food and Drug Administration approval of seven new molecular targeted 
agents over the past 7 years. Axitinib is a potent, selective, second-generation inhibitor of vascular 
endothelial growth factor receptors and the latest to join the armamentarium of drugs available 
for the treatment of metastatic RCC. Despite recent advances in the development of molecular 
targeted agents for metastatic RCC, the ideal sequencing of these agents remains unclear.
Keywords: metastatic RCC, vascular endothelial growth factor receptor inhibitor, molecular 
targeted agent, clear-cell carcinoma
Introduction
Kidney cancer is the fourteenth most common cancer worldwide, with an estimated 
273,500 new cases diagnosed in 2008.1 Renal cell carcinoma (RCC) accounts for 90% 
of all kidney cancers with conventional clear-cell carcinoma being the predominant 
subtype (75%–80%).
Interferon-α (IFN-α) and interleukin-2 (IL-2) treatments have shown poor response 
rates (,15%), with only modest improvement in overall survival (OS).2 Treatment with 
IL-2 has shown prolonged remission (arguably, cure) in a small percentage of patients 
but is associated with considerable treatment-related morbidity and mortality. High-
dose IL-2 has shown durable complete remission in approximately 5% of patients but 
has never demonstrated improvement in OS in a randomized controlled trial.2,3
A growing understanding of the biology of RCC has led to the development and 
US Food and Drug Administration (FDA) approval of seven new agents targeting 
specific growth pathways. Targets for RCC therapy (Figure 1) include Von Hippel–
Lindau (VHL)-mediated pathways – vascular endothelial growth factor (VEGF), 
epidermal growth factor receptor (EGFR), mammalian target of rapamycin (mTOR), 
platelet-derived growth factor (PDGF) – and non-VHL mediated pathways, such as 
Raf-kinase, phosphatidylinositol 3-kinase, and Akt. This review aims to summarize 
the systemic treatment options for first- and second-line treatment of metastatic renal 
cell carcinoma (mRCC), with a focus on axitinib, the most recent drug to be approved 
by the FDA for this indication.
Molecular pathogenesis
Environmental and clinical factors such as smoking, obesity, occupational expo-
sure to toxic compounds (cadmium, asbestos, and petroleum byproducts), and 
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analgesic abuse have been implicated in the etiology of 
RCC. Several inherited disorders including hereditary 
papillary renal cancer, VHL disease, and Birt–Hogg–Dubé 
syndrome predispose to a higher risk of RCC development. 
VHL disease, an autosomal dominant disorder, is associ-
ated with structural abnormalities on chromosome 3p 
and is characterized by a predisposition to a variety of 
neoplasms, including RCC. Most patients with primary 
sporadic clear-cell RCC have either mutations or silenc-
ing of the VHL tumor-suppressor gene.4 VHL inactivation 
simulates hypoxic conditions  leading to accumulation of 
hypoxia-inducible factor (HIF)-1 α. HIF-1 α binds to 
HIF-1 β, forming a transcriptional factor complex, which 
translocates to the nucleus and facilitates production of 
multiple growth factors including VEGF and PDGF. These 
growth factors subsequently bind to specific tyrosine kinase 
receptors (vascular endothelial growth factor receptor 
[VEGFR]-1, VEGFR-2, VEGFR-3, and platelet-derived 
growth factor receptors [PDGFRs]) resulting in cell migra-
tion, endothelial cell growth, and proliferation. mTOR, 
a serine/threonine-specific kinase is involved in multiple 
tumor-promoting intracellular signaling pathways in RCC. 
Figure 1 Biological pathways and targets for molecular targeted agents in renal cell carcinoma.
Abbreviations: APK, activated protein kinase; BNiP3, BCL2/adenovirus E1B 19 kDa protein-interacting protein 3; CA iX, carbonic anhydrase iX; EGFR, epidermal growth factor 
receptor; EPO, erythropoietin; ERK, extracellular signal-regulated kinase; GLUT1, glucose transporter 1; HiF, hypoxia-inducible factor; MAPK, mitogen-activated protein kinase; 
MEK, mitogen-activated protein kinase kinase; mTOR, mammalian target of rapamycin; Pi3K, phosphatidylinositol 3-kinases; PDGF, platelet-derived growth factor; PDGFR, 
platelet-derived growth factor receptor; TGF, transforming growth factor; vEGF, vascular endothelial growth factor; vEGFR, vascular endothelial growth factor receptor.
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mTOR inhibition also exhibits antiangiogenesis activity by 
reducing levels of HIF-1 α and VEGF.5
Current first-line systemic 
treatment of mRCC
Results of the pivotal Phase III clinical trials of molecular 
targeted agents that are FDA approved for use in the first-
line treatment of patients with mRCC are summarized in 
Table 1.
Sunitinib
Sunitinib is an orally available multi-kinase inhibitor with 
potent activity against VEGFRs (types 1–3), PDGFR (α, β), 
and c-Kit oncogene. In a multicenter Phase III randomized 
controlled trial of 750 treatment-naïve patients with good/
intermediate prognosis mRCC, treatment with sunitinib 
(50 mg daily for 4 weeks followed by a 2-week break) was 
associated with an improvement in progression-free sur-
vival (PFS) (11 vs 5 months; P , 0.001) and OS (26.4 vs 
21.8 months; P = 0.05) when compared with IFN-α.6
Pazopanib
Pazopanib is an oral angiogenesis inhibitor targeting VEGFR, 
PDGFR, and c-Kit oncogene. The pivotal Phase III ran-
domized double-blind placebo-controlled trial evaluated 
the efficacy and safety of pazopanib in treatment-naïve 
and cytokine-pretreated patients (n = 435) with advanced 
RCC. Treatment with pazopanib demonstrated an improved 
objective response rate (ORR) (30% vs 3%; P , 0.001) 
and median PFS (9.2 vs 4.2 months; P , 0.0001) when 
compared to placebo.7
Temsirolimus
Temsirolimus is a parenterally administered rapamycin 
analog that functions as a competitive inhibitor of mTOR 
kinase. Temsirolimus was evaluated in a Phase III trial in 
which 626 previously untreated poor-prognosis patients 
with metastatic or recurrent RCC were randomly assigned 
to temsirolimus (25 mg intravenously/week), temsirolimus 
(15 mg intravenously/week) plus IFN-α (escalated up to 
6 million units three times/week as tolerated), or IFN-α 
monotherapy (escalated up to 18 million units three times/
week as tolerated). Temsirolimus significantly prolonged 
the median PFS (3.1 vs 5.5 months) and median OS (7.3 vs 
10.9 months; hazard ratio [HR] 0.73, 95% confidence inter-
val [CI] 0.58–0.92; P = 0.008) when compared with single-
agent IFN-α.8
Bevacizumab
Bevacizumab is a monoclonal antibody that binds circulating 
VEGF and prevents its interaction with VEGFR. Two simi-
larly designed Phase III trials have demonstrated improved 
PFS with bevacizumab plus IFN-α compared with IFN-α 
alone. In the avastin and roferon for renal cell carcinoma 
(AVOREN) trial, 649 treatment-naïve mRCC patients were 
randomized to IFN-α (9 million units three times/week) plus 
either bevacizumab (10 mg/kg every 2 weeks) or placebo. 
Median PFS was significantly improved in the bevacizumab 
plus IFN-α arm in comparison to the control group (10.2 vs 
5.4 months; HR 0.63, 95% CI 0.52–0.75; P = 0.0001).9 Final 
analysis showed a median OS of 23.3 months with beva-
cizumab plus IFN-α and 21.3 months with IFN-α plus 
placebo (HR 0.91, 95% CI 0.76–1.10; P = 0.3360).10 In the 
Cancer and Leukemia Group B (CALGB) trial 90206, 732 
Table 1 Summary of Phase III clinical trial results for targeted agents approved for first-line treatment of metastatic renal cell 
carcinoma
References Indication n Drugs OR (CR + PR) 
(%)
Median PFS 
(months)
P value Median OS 
(months)
P value
Motzer et al6 Treatment naïve 750 Sunitinib 47 11 ,0.001 26.4 0.051
iFN-α 12 5 21.8
Sternberg et al7 Treatment naïve and 
cytokine pretreated
435 Pazopanib 30 9.2 ,0.0001 NR
Placebo 3 4.2
Escudier et al9 Treatment naïve 649 Bevacizumab + iFN-α 31 10.4 0.0001 23.3 0.3360
iFN-α 12 5.5 21.3
Rini et al11 Treatment naïve 732 Bevacizumab + iFN-α 25.5 8.5 ,0.0001 18.3 0.097
iFN-α 13.1 5.2 17.4
Hudes et al8 Treatment naïve 626 Temsirolimus (25 mg/wk) 8.6 5.5 10.9
Temsirolimus (15 mg/wk) + 
iFN-α
8.1 4.7 8.4
iFN-α 4.8 3.1 7.3
Abbreviations: CR, complete response; iFN, interferon; OR, objective response; OS, overall survival; PFS, progression-free survival; PR, partial response.
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treatment-naïve patients with mRCC were randomly assigned 
to IFN-α plus bevacizumab or IFN-α plus placebo on sched-
ules similar to those used in the AVOREN trial. There was 
a statistically significant increase in the ORR (25.5 vs 13.1 
percent) and median PFS (8.5 vs 5.2 months; HR 0.71, 95% 
CI 0.61–0.83) for the bevacizumab plus IFN-α arm.11 The 
final analysis of this trial revealed a trend toward improved 
median OS (18.3 vs 17.4 months; HR 0.86; P = 0.07) for the 
bevacizumab plus IFN-α arm.12
Second-line clinical trials
Sorafenib
Sorafenib is a potent small molecule multi-kinase inhibitor of 
VEGFR-2, fms-like tyrosine kinase receptor-3, PDGFR, and 
fibroblast growth factor receptor-1. In the Phase III Treatment 
Approaches in Renal Cancer Global Evaluation Trial (TAR-
GET), in which 903 patients with advanced RCC who had failed 
prior standard therapy (IFN-α or IL-2) were randomly assigned 
to sorafenib (400 mg orally twice daily) or placebo. There 
was a significant prolongation of median PFS in the sorafenib 
arm (5.5 vs 2.8 months; HR 0.44, 95% CI 0.35–0.55) but no 
significant difference in the median OS between the two arms 
(17.8 vs 15.2 months; HR 0.88, 95% CI 0.74–1.04).13
Everolimus
Everolimus is an orally administered selective inhibitor of 
mTOR, a key serine-threonine kinase that plays an essential 
role in downstream protein synthesis of the PI3K/AKT 
pathway; is dysregulated in many human cancers; and is an 
essential component of an intracellular signaling pathway 
regulating cell growth and proliferation, metabolism, and 
angiogenesis. Everolimus is a derivative of rapamycin and 
has been in clinical development since 1996 as an immuno-
suppressant in solid organ transplantation. The encouraging 
Phase II clinical trial results in RCC led to the development 
of the pivotal Phase III clinical trial, RECORD-1.
This trial, a Phase III randomized study, assessed the 
efficacy of everolimus in patients with mRCC and disease 
progression on or within 6 months of stopping treatment with 
sunitinib or sorafenib, or both. A total of 410 patients were 
randomized in a 2:1 ratio to receive everolimus (10 mg daily) 
or placebo. The trial was terminated early by the Independent 
Data Monitoring Committee as an interim analysis demon-
strated a significant difference in PFS between the two arms 
(4.9 vs 1.9 months with everolimus and placebo, respectively; 
P , 0.001). The improvement in PFS extended to all stratifi-
cation sets irrespective of risk group, prior treatment status, 
age, or sex. No complete responses were observed; the partial 
response rate was 1.8% (n = 5) with everolimus and 0% with 
placebo. Although Response  Evaluation Criteria In Solid 
Tumors-defined objective responses were rare (,2%) with 
everolimus, any reduction in tumor measurement from baseline 
as best percentage change was observed in 47% of patients 
treated with everolimus versus 10% with placebo. Stable dis-
ease by independent central review was noted in 185 (66.8%) 
of 277 patients in the everolimus arm versus 45 (32.4%) of 
139 in the placebo arm. Based on these results, everolimus 
has been recommended as a second-line treatment option for 
metastatic clear-cell RCC patients who have failed first-line 
VEGFR-tyrosine kinase inhibitor (TKI) treatment.14
The median OS was 14.8 months for the everolimus arm 
versus 14.4 months for the placebo arm (HR 0.87; P = 0.162). 
The lack of significant difference in survival could be 
explained by the degree of crossover after the un-blinding 
of the trial following interim analysis; 76% of patients in the 
placebo arm had crossed over to everolimus.15 Preplanned, 
prospective subgroup analysis compared the efficacy of 
everolimus in patients who received one previous VEGFR-
TKI treatment to those who received two or more (26%).16 
Of the patients who had received one previous VEGFR-TKI 
treatment, median PFS was 5.4 months with everolimus 
and 1.9 months with placebo (HR 0.32, 95% CI: 0.24–0.43; 
P , 0.001). Of the patients who had received two previous 
VEGFR-TKI treatments, the median PFS was 4.0 months 
with everolimus and 1.8 months with placebo (HR 0.32, 
95% CI 0.19–0.54; P , 0.001). The authors concluded that 
everolimus was associated with prolonged PFS relative 
to placebo in patients who received one or two previous 
VEGFR-TKI treatments. Patients who had received only one 
previous VEGFR-TKI treatment had apparently longer PFS 
with everolimus in comparison with those who had received 
two previous VEGFR-TKI treatments.
Axitinib
Axitinib (Inlyta®, Pfizer, New York, NY, USA; AG-013736) 
(Figure 2) is a potent, selective, second-generation inhibitor of 
VEGFR-1, -2, and -3; PDGF; and colony stimulating  factor-1 
receptor tyrosine kinases.17,18 Axitinib is 50–450 times more 
potent than the first-generation VEGFR inhibitors. Based 
on pharmacokinetic/pharmacodynamic analysis, axitinib 
appears to be a selective VEGFR-TKI according to current 
clinical exposure.19
Phase i clinical trials
A Phase I study by Rugo et al investigated the efficacy, 
safety, and pharmacokinetics of axitinib in advanced  cancer.20 
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 Thirty-six patients received axitinib at doses between 5 and 
30 mg twice daily. Dose-limiting toxicities included hyperten-
sion, hemoptysis, and stomatitis. Axitinib was absorbed rap-
idly, with plasma peak concentrations noted within 2–6 hours 
of dosing and steady plasma pharmacokinetic state within 
15 days. Three confirmed partial responses were noted. This 
study recommended the maximum-tolerated dose and recom-
mended Phase II dose of axitinib to be 5 mg twice daily.
Phase ii clinical trials
A Phase II multicenter study by Rini et al21 investigated the 
efficacy and safety of axitinib in patients with sorafenib-
refractory metastatic RCC. The starting dose of axitinib was 
5 mg twice daily and dose escalation was possible in 53.2% 
of patients. Of the 62 patients, overall response rate was 
22.6%, with a median duration of response of 17.5 months. 
The median PFS was 7.4 months (95% CI 6.7–11.0) and the 
median OS was 13.6 months (95% CI 8.4–18.8 months). 
The most common grade 3/4 adverse events included 
hand-foot syndrome (16.1%), fatigue (16.1%), hyperten-
sion (16.1%), dyspnea (14.5%), and diarrhea (14.5%). 
Post-hoc analysis of this study by Dutcher et al revealed 
an ORR of 7.1% for patients with prior treatment with 
sunitinib and sorafenib, 27.6% for patients with prior 
cytokines and sorafenib, and 25% for prior treatment with 
sorafenib alone.22
In a Phase II study by Rixe et al, 52 patients with mRCC 
who had failed at least one cytokine-based treatment were 
treated with axitinib 5 mg twice daily.23The primary endpoint 
was objective response (complete plus partial response) and 
secondary endpoints included duration of response, time to 
progression (TTP), OS, and patient-reported health-related 
quality of life.24 Results demonstrated an ORR of 44.2% 
(95% CI 30.5–58.7), with a median response duration of 
23.0 months (20.9–not estimable; range 4.2–29.8). Median 
TTP was 15.7 months (95% CI 8.4–23.4) and the median 
OS was 29.9 months (95% CI 20.3–not estimable). The 
updated 5-year survival rate was 20.6% (95% CI 10.9–32.4).22 
The most common treatment-related grade 3/4 toxicities 
included fatigue (21.2%), diarrhea (19.2%), and hyperten-
sion (15.4%).
The results of these Phase II trials (Table 2) suggested 
that axitinib could be an effective second-line treatment in 
patients with advanced RCC and led to the development of 
the pivotal Phase III trial.
Phase iii clinical trial
Axitinib versus sorafenib in advanced renal cell carcinoma 
(AXIS), a multicenter Phase III randomized controlled trial, 
which compared axitinib to sorafenib in patients with mRCC 
who had progressed despite first-line therapy containing 
sunitinib, bevacizumab plus IFN-α, temsirolimus, or cytok-
ines.25 A total of 723 patients with metastatic clear-cell RCC 
were randomized 1:1 to either axitinib (5 mg twice daily) or 
sorafenib (400 mg twice daily). Dose increments of axitinib 
to 7 mg and then to 10 mg were allowed for patients without 
hypertension or adverse reactions above grade 2. The median 
duration of treatment was 6.4 months (range 0.03–22) in the 
axitinib arm and 5.0 months (range 0.03–20) in the sorafenib 
arm. The median PFS was 6.7 months (95% CI 6.3–8.6) for 
axitinib versus 4.7 months (95% CI 4.6–5.6) for sorafenib 
(HR 0.665, 95% CI 0.544–0.812; P , 0.0001). In cytokine-
pretreated patients, the median PFS was 12.1 months for 
axitinib versus 6.5 months for sorafenib (HR 0.464, 95% CI 
0.318–0.676; P , 0.0001). In sunitinib-pretreated patients, 
the median PFS was 4.8 months for axitinib and 3.4 months 
for sorafenib (HR 0.741, 95% CI 0.573–0.958; P = 0.0107). 
In the overall patient population and the two main subgroups 
(prior sunitinib treatment and prior cytokine treatment), 
there was a statistically significant advantage for axitinib 
over sorafenib for the primary endpoint of PFS.
The median OS was 20.1 months (95% CI 16.7–23.4) 
for axitinib versus 19.2 months (95% CI 17.5–22.3) for 
sorafenib. In the sunitinib-pretreated patients, the median 
OS was 15.2 months (95% CI 12.8–18.3) in the axitinib 
arm and 7.7 months (95% CI 4.4–12.4) in the sorafenib 
arm. In the cytokine-pretreated patients, the median OS was 
29.4 months (95% CI 24.5–not reached) in the axitinib arm 
and 27.8 months (95% CI 23.1–34.5) in the sorafenib arm. 
There were no statistically significant differences between 
Figure 2 Chemical structure of axitinib.
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the arms in terms of OS in the overall population or in the 
subgroups by prior therapy.
The ORR assessed by blinded independent radiology 
review was 19.4% for axitinib and 9.4% for sorafenib 
(P = 0.0001). The objective response to axitinib in the 
sunitinib-pretreated patients was 11.3% (95% CI 7.2–16.7) 
and in the cytokine-pretreated patients was 32.5% (95% CI 
24.5–41.5). The median duration of response was 11 months 
(95% CI 7.4–not reached) for axitinib and 10.6 months for 
sorafenib (8.8–11.5). The open-label trial design and the 
potential for dose escalation in the axitinib arm have been 
criticized. However, it is still unclear if there is any additional 
benefit of axitinib dose escalation and this is the subject of 
an ongoing Phase II trial.26
Secondary end points of the trial included kidney-specific 
symptoms, function assessments, and heath-related qual-
ity of life. The composite end point of time to deteriora-
tion using patient questionnaires (Functional Assessment 
of Cancer Therapy – Kidney Cancer Symposium Index 
[FKSI-15]) demonstrated a statistically significant advan-
tage for axitinib when compared with sorafenib (HR 0.829, 
95% CI 0.707–0.993; P = 0.020).27 The authors concluded 
that treatment with axitinib led to a statistically significant 
improvement in PFS along with a delay in worsening of 
composite time-to-deterioration end points when compared 
with sorafenib in treatment-refractory RCC.
Discussion
Axitinib is a potent and selective VEGFR-TKI, which has 
demonstrated significant antitumor activity in patients with 
mRCC. Data from the pivotal AXIS trial makes a compelling 
case for its use as second-line treatment following failure of 
previous IFN-α or TKI therapy.25 Based on the results of this 
trial, the FDA (January 2012) and European Medicines Agency 
(September 2012) approved the use of axitinib for the treatment 
of advanced RCC after failure of one prior systemic therapy. 
AXIS is the first trial to have demonstrated the superiority of 
one targeted agent over another in mRCC in the second-line 
setting following failure of one prior  systemic therapy. The 
efficacy of axitinib versus sorafenib in the first-line setting is 
being investigated in a Phase III trial of patients with mRCC 
who are either treatment naïve or have progressed after one 
therapy.28 Results from the TARGET trial are unlikely to influ-
ence management in the current era, as the standard first-line 
treatment on the trial was either IFN-α or IL-2. Results from 
the nexavar versus torisel as second-line therapy for advanced 
renal cell carcinoma (INTORSECT) trial, which compared 
the efficacy of temsirolimus versus sorafenib as second-line 
treatment in patients with mRCC were recently presented at the 
Thirty-Seventh Congress of the European Society of Medical 
Oncology in October 2012.29 Results from this trial showed no 
significant difference in median PFS (4.28 vs 3.91 months) or 
OS (12.27 vs 16.64 months) for patients treated with temsi-
rolimus and sorafenib, respectively.
The drug choice in the second-line setting remains unclear, 
as results from the RECORD-1, AXIS, and INTORSECT tri-
als leave many questions unanswered. In the AXIS trial, the 
improvement in median PFS was less pronounced in patients 
receiving first-line sunitinib (4.8 vs 3.4 months; HR 0.741; 
P = 0.010) when compared with patients receiving first-line 
cytokines (12.1 vs 6.5 months; HR 0.464; P , 0.0001). In 
the real-world scenario, the post-cytokine cohort is dwindling 
rapidly, as targeted agents are becoming increasingly available 
worldwide, either as standard treatment or as part of clinical 
trials. RECORD-1 and AXIS are two very different clinical tri-
als and it would be difficult to directly compare outcomes.
The rapidity of drug development in this setting makes 
it difficult to choose the ideal comparator for randomized 
clinical trials for patients with mRCC. The ideal comparator 
for the AXIS trial would have been everolimus, but it was not 
FDA approved until May 2009. Both everolimus and axitinib 
have demonstrated significant benefit in patients with mRCC 
who have progressed after at least one line of systemic therapy, 
albeit in a different patient population. Patients in the AXIS 
trial had only failed first-line therapy whereas nearly 80% 
of patients in the RECORD-1 trial were heavily pretreated. 
In addition to VEGFR inhibitors, patients in the everolimus 
arm were previously treated with immunotherapy (65%), 
Table 2 Summary of second-line Phase ii clinical trials of Axitinib in metastatic renal cell carcinoma
References Previous 
treatments
Drugs n OR (%) Median PFS 
(months)
OS 
(months)
Rini et al22 Sorafenib Axitinib 5 mg bd 62 22.6 7.4 (95% Ci 6.7–11) 13.6 (95% 
Ci 8.4–18.8)
Rixe et al23 and 
Motzer et al24
Cytokines Axitinib 5 mg bd 52 44.2 15.7 (95% Ci 8.4–23.4) 29.9 (95% 
Ci 20.3–NR)
Abbreviations: CI, confidence interval; NR, not reached; OR, objective response; OS, overall survival; PFS, progression-free survival.
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chemotherapy (13%), and hormonal therapy (2%). The ideal 
sequencing of axitinib and everolimus following failure of one 
TKI remains a challenge and perhaps could only be addressed 
by a randomized Phase III trial.
Conclusion
The FDA has approved seven new drugs over the past 7 years, 
heralding the unprecedented drug development now being 
undertaken for the management of RCC. Axitinib is the most 
recent drug to have received FDA approval and is indicated 
for the treatment of advanced RCC after failure of one prior 
systemic therapy. Although the AXIS trial met its primary 
end point of improved PFS, the magnitude of median PFS 
improvement was more pronounced in the prior cytokine-
treatment group when compared with the prior sunitinib-
treatment group. There were no statistically significant 
differences between the treatment arms in terms of OS in 
the overall population or in the subgroups by prior therapy. 
Indirect comparisons between the efficacy of everolimus and 
axitinib are unlikely to be helpful, given the differences in 
the trial populations. Both everolimus and axitinib are potent 
drugs in this patient population and the ideal sequencing of 
drugs in the second-line setting can only be determined by a 
head-to-head comparison between these agents.
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